Joey Bose的动态

PoundsPunch’s July Periodical is Now Available! This month, we have witnessed a surge in regulatory responses to weight loss drugs at both federal and state levels—from a House panel passing a bill to allow Medicare coverage, to President Biden and Senator Sanders calling for actions to curb the sky-high prices of these drugs. Novo Nordisk’s CEO has also agreed to testify before the Senate in September. Additionally, Eli Lilly’s Mounjaro has been approved by Chinese regulators to enter the largest obesity and diabetes market in the world. What will be the impact if the bill becomes law for insurers, providers, and patients? Will Lilly’s approval in China signify another rapid growth phase, especially given the Chinese regulators' aggressive pricing policies to include drugs in their formulary? Let’s explore. In the July Periodical, you will discover: -House Panel Passes Bill: Expanding Medicare coverage for obesity drugs. Increased Access to Treatments: Insurers are expanding access to weight loss surgery. -Calls for Lower Drug Prices: Initiatives by Biden and Sanders for pharmaceuticals to reduce the cost of weight loss drugs. -Legislation to Reduce Drug Costs: The Senate passed a bill to limit the number of patents a manufacturer can hold. -CEO Testimony: Novo Nordisk’s CEO will testify before the U.S. Senate on September 24. -State Regulations Tighten: States are increasing regulations on compounding weight loss drugs. -Patient Adherence Challenges: 75% of patients stop using weight loss drugs within two years. -Eli Lilly’s Market Expansion: The company’s weight loss drug has been approved by Chinese regulators. https://lnkd.in/gEGspHhR

25,000 NEW people are starting to take #Wegovy, every week. That is 1.3M new people this year. Elly Lilly and others have similar growth expectation data to support growth in taking these GLP-1s. The shift from utilization as diabetic medications to weight loss medications is happening. #IndicationNation. The rise of the usage of GLP-1s is not short term and will not dwindle as quickly as blockbuster HEP C cures. Employers will need solid solutions to help plan sponsor's provide access where appropriate. Let's talk. #PBM, #GLP-1, Transparency-Rx, MedOne Pharmacy Benefit Solutions, Credit to CNN for the article below.

Colleagues, I am pleased to inform you that UroPharma has successfully completed another major step?on the road to bringing our innovative #bladder drug-device #deliverysystem to market. From the perspective of #regulatory approval, we are now in the final stretch with, only one more hurdle to jump before we submit our intermittent drug-delivery device for the UKCA mark in order to launch in the UK market. ? With the UKCA mark, the dtb-instilla will allow clinicians to provide intravesical (direct-to-bladder) drug delivery treatments to patients through a licensed device, providing better treatments?whilst avoiding the major problems associated with the oral delivery of #antibiotics and other drugs for #bladdermanagement. ? Human factors (HF) studies of the?dtb-instilla intermittent device, both formative and summative, now have been completed in?the UK. The latter one also validated that our instructions for use (IFU) document is suitable for?incorporation with the product. Positive results on both of these aspects are compliance?requirements for the device to?enter the market. The conclusion from the latest study was that: “When considered as a whole, the test?outcomes provide evidence that the dtb-instilla intermittent device can be safely and?effectively used for intravesical administration of medication for bladder?management”. ? Our current?intention is to launch the dtb-instilla onto the UK market in the first quarter of 2025 with only #biocompatibility studies ahead of us before we can submit for the UCKA mark we continue to seek #investment, so if you would like further information, especially given that we now?have these positive results from the human factors studies, then please contact me.? ? The sooner we can get to market the sooner we can start helping patients who are suffering from the often life changing effects of bladder conditions and diseases and the sooner we can contribute to the overall campaign against #antimicrobialresistance that threatens the future of our #healthcare.

One of the big, unanswered questions about the IRA is whether PBMs will use subtle formulary manipulation to push patients away from price-controlled drugs to higher-priced medicines that might drive more PBM profits. Part of the reason that this is a concern is that the PBMs already have a track record of pulling these kinds of shenanigans. There's a great piece of circumstantial evidence in the annual Association for Accessible Medicines savings report, which looked at how often generic drugs in Medicare are placed on the "generic formulary tier." Just a few years ago, about two-thirds of generics were on the generic tier. Now, less than a decade later, that ratio has flipped: more often than not, generic drugs are not on the generic tier. Things that make you go "hmmmmm."

?? Weight loss meds like GLP-1s are a breakthrough, but Big Pharma's pricing is a major roadblock! Discover how PBMs are stepping in with innovative programs to help manage costs and improve patient outcomes. Read more: https://lnkd.in/en23Pq_3

You may have seen "Drug Middlemen Push Patients to Pricier Medicines, House Probe Finds" in the Wall Street Journal. Pharmacy Benefit Managers (PBMs) are middlemen between company health plans and Pharma companies. As costs go up, so do their profits. ?? On average, an employer's pharmacy expenditure is 25% of the total claims cost, with some as high as 50-60%. ?? Join this webinar to learn more about the contributors driving higher costs and innovations to get a fair price at the pharmacy. The discussion will include: ? Strategies to better manage pharmacy costs ? Navigating and understanding the delicate balance between coverage and costs. ? The future of the FDA drug pipeline This webinar is approved for 1 hour of SHRM credit Register now: https://bit.ly/4f4OU7z

You may have seen "Drug Middlemen Push Patients to Pricier Medicines, House Probe Finds" in the Wall Street Journal. Pharmacy Benefit Managers (PBMs) are middlemen between company health plans and Pharma companies. As costs go up, so do their profits. ?? On average, an employer's pharmacy expenditure is 25% of the total claims cost, with some as high as 50-60%. ?? Join this webinar to learn more about the contributors driving higher costs and innovations to get a fair price at the pharmacy. The discussion will include: ? Strategies to better manage pharmacy costs ? Navigating and understanding the delicate balance between coverage and costs. ? The future of the FDA drug pipeline This webinar is approved for 1 hour of SHRM credit Register now: https://bit.ly/4f4OU7z

Medicare, which provides health coverage to over 67 million Americans, recently disclosed the first-ever negotiated prices for ten high-cost drugs. These prices, effective in 2026, are projected to save the U.S. government $6 billion in the first year alone. #generics #antitrust #competitionlaw #biosimilar #medicine #generidrugs #competitionlaw

Our Senior Director of Value Delivery Gavin Magaha recently shared his thoughts with readers of Drug Channels Institute, an HMP Global company on the direction of the discount drug market, which is very much destabilized at the moment. Changes regarding the Inflation Reduction Act’s maximum fair price rule and Medicare Part B and Part D inflationary rebate penalties -- not to mention the uncertainty around the 340B program -- are causing a lot of uncertainty among stakeholders. Gavin explains the ramifications of the various directions the market could go and how greater certainty, transparency and trust could be built through additional technology and data to meet new tight timelines and an expanded need for medications. His full article is here: https://lnkd.in/gJVmwDVx Gavin’s article also references an updated report by Kalderos: “Operational Complexity and Evolving Challenges: What Drug Manufacturers Need to Know Now About Drug Discount Programs, the Inflation Reduction Act, and 340B,” which is available here: https://lnkd.in/gwUd-VXC #DrugDiscountMarket #340B #InflationReductionAct #MFP #MDRP